Roche

News

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.

News

Roche buys AI-powered diagnostics player PathAI

Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy it for $1.05bn.

News

Swiss franc strength puts Roche's results in a poor light

Roche has started its financial reporting for 2026 with a 5% fall in first-quarter revenues, but says its underlying performance remains strong.

News

New data build case for Roche's oral BTK drug for MS

Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

News

FDA kicks off review of Roche's Gazyva for wider lupus use

Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.

News

Roche places a $1bn bet on C4T degrader-antibody conjugates

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

Roche buys AI-powered diagnostics player PathAI

Swiss franc strength puts Roche's results in a poor light

New data build case for Roche's oral BTK drug for MS

FDA kicks off review of Roche's Gazyva for wider lupus use

Roche places a $1bn bet on C4T degrader-antibody conjugates

Novo Nordisk fight with KBP Bio will go to arbitration

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks